サンプル依頼リスト カート
  • English
  • Korean
表紙：全身型若年性特発性関節炎の世界市場-2023年～2030年
市場調査レポート
商品コード
1345451

全身型若年性特発性関節炎の世界市場-2023年～2030年

Global Systemic Juvenile Idiopathic Arthritis Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
全身型若年性特発性関節炎の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の全身型若年性特発性関節炎の市場規模は、2022年に8億7,000万米ドル、2030年までに11億9,000万米ドルに達すると予測されています。

若年性特発性関節炎（JIA）は、子供や10代の若者に非常によく見られるタイプの関節炎です。若年性特発性関節炎の約10％から20％は、全身型若年性特発性関節炎（SJIA）と呼ばれるまれで重篤な亜型です。「全身型」とは、関節だけでなく、肝臓、肺、心臓など、体の他の部分にまで影響を及ぼす可能性があることを示しています。SJIAはしばしばスティル病と呼ばれ、小児期のいつでも発症する可能性があります。

最も典型的な発症時期は約2歳ですが、男性も女性も同じように影響を受けます。SJIAはまた、自己免疫疾患ではなく自己炎症性疾患とみなされる点で、異なる亜型間で異なります。SJIAは、他のタイプの若年性特発性関節炎と比較して、さらに極端であり、解釈や治療がより困難です。多くの患者にとって生涯続く疾患であり、成人期まで続くこともあります。

認可の増加、研究活動からの好結果、合併・買収を含む市場開拓、製品のイントロダクション、認知度の高まりなどが、予測期間中の世界の全身型若年性特発性関節炎市場の成長を後押しすると予想されます。さらに、症例の増加と研究資金の拠出も、予測期間における世界市場の成長に貢献すると期待されています。

ダイナミクス

製品承認の増加と前向きな研究成果

製品承認の増加や、明確な臨床試験による良好な結果が、予測期間における世界市場の成長を押し上げると予想されます。例えば、2023年1月、中国の国家医薬品監督管理局（NMPA）は、インターロイキン-6受容体（IL-6R）を標的とするように設計された組み換えヒト化モノクローナル抗体であるBio-Thera Solutionのアクテムラ（トシリズマブ）のバイオシミラー、BAT1806を承認しました。サイトカイン放出症候群（CRS）、関節リウマチ（RA）、全身型若年性特発性関節炎（sJIA）の治療薬として承認されています。FDAとEMAはBAT1806/BIIB800の販売承認申請を受理しました。

さらに、最近の研究によると、完全ヒト型抗インターフェロン-γ（IFNγ）薬であるエマパルマブは、アナキンラ（キネレット；Sobi社）および／またはシクロスポリンを併用した、または併用しない高用量グルココルチコイドによる通常の治療で効果が得られなかった患者において、全身型若年性特発性関節炎（sJIA）または成人発症スティル病（AOSD）に続発するマクロファージ活性化症候群（MAS）の寛解を引き起こす有効性を示しました。エマパルマブは、フランス、イタリア、スペイン、英国、米国の5ヵ所で実施された第2相非盲検単群試験（NCT03311854）で検討されました。

各団体による取り組みの増加

若年性特発性関節炎（JIA）および関連疾患の全体的な管理を強化するために、異なる学会からの取り組みが増加しています。例えば、2023年3月、カナダリウマチ学会（CRA）は、若年性特発性関節炎（JIA）関連ぶどう膜炎のスクリーニング、モニタリング、治療に関する方針を公表しました。JIA関連ぶどう膜炎における全身療法を評価する研究は、統一された治療手順と新規治療に対する規制当局の認可にもかかわらず、制限されています。

米国リウマチ学会（ACR）/関節炎財団（AF）の方針は、画期的な治療法を十分に利用するために、地域、州、連邦の規制当局と支払者に教育とロビー活動の可能性を提供しています。カナダにおけるJIA関連ぶどう膜炎のモニタリングとコントロールに関する専門家の合意規範が利用可能になることは、国全体で最も高い標準治療を正常化する助けとなることが期待されます。

さらに、最近開催された米国リウマチ学会（ACR）のコンバージェンス2021サミットでは、若年性特発性関節炎（JIA）の成人患者をどのように扱うかについて、成人リウマチ医を対象とした魅力的な議論が行われました。さらに、NICE（National Institute for Health and Care Excellence）は2021年9月、2歳以上の活動性多関節型若年性関節炎および若年性乾癬性関節炎の治療薬としてトファシチニブ（別名ゼルヤンツ、ファイザー製）を選択するよう最終勧告案を発表しました。

全身型若年性特発性関節炎の高額な治療費

全身型若年性特発性関節炎の高い治療費は、予測期間における世界市場の成長を妨げると予想されます。例えば、JIAの治療費は高額になる可能性があり、特に、Pediatric Rheumatology誌の2021年の研究によると、米国でJIAの若年者を管理するための年間総額は300米ドルから45,000米ドル近くまで変動する可能性があります。さらに、生物学的製剤であるノバルティスのイラリスは、1回の投与ごとに16,000米ドルから37,000米ドルがかかります。小バイアルの費用は保険適用範囲によって異なります。

さらに、若年性特発性関節炎患者の家族の年間支出は1,122米ドルから44,832米ドルであり、最も高額なのは薬代と診察費です。全身型若年性特発性関節炎にかかるこれらの高額な費用は、影響を受けた人々の大多数を置き去りにし、世界市場の成長を妨げています。

疾患の低い有病率

全身型若年性特発性関節炎の有病率の低さは、予測期間中の世界市場の成長を妨げると予想されます。例えば、ニュージーランドにおける若年性特発性関節炎の年間発症率は5.1/100,000であり、国際リウマチ学会（ILAR）の基準に従って分類され、そのうち乏関節炎が47％、多関節炎が26％であり、これらは解釈の直近6ヵ月以内にそれぞれ4関節以下と5関節以上の関節炎で代表される最も典型的なサブタイプです。あまり期待されないサブタイプとしては、15％の症例が腱炎関連関節炎、8％の症例が全身型JIA、3％の症例が乾癬性関節炎でした。

JIAの存在は、欧州の小児では10万人あたり7.2人とかなり増加していますが、マオリや太平洋諸島の小児では、頸部病変、びらん性変化、共通領域狭小化、リウマチの特徴陽性障害など、欧州の小児に対応する不十分な予測的特徴を提供する可能性が有意に高いです。欧州では、SJIAを発症する小児は毎年10万人に1人以下と推定されています。現在、10万人に5人から15人がSJIAに罹患していると推定され、世界中で男の子も女の子も同じように影響を受けています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品承認の増加と前向きな調査結果
      • 各団体による取り組みの増加
    • 抑制要因
      • 全身型若年性特発性関節炎の高額な治療費
      • 疾患の有病率の低さ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • 技術動向
  • エンドユーザー動向
  • SWOT分析
  • DMIの見解

第6章 COVID-19分析

第7章 治療タイプ別

  • 薬物治療
    • 抗炎症薬（NSAIDS）
    • 腫瘍壊死因子（TNF）遮断薬
    • 筋弛緩薬
    • 免疫抑制薬
    • 疾患修飾性抗リウマチ薬
    • その他
  • 生物製剤
  • その他

第8章 投与経路別

  • 経口剤
  • 注射剤
  • その他

第9章 年齢階級別

  • 乳児
  • 幼児
  • 青少年

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 学術研究センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Novartis AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Ltd.
  • Genetech, Inc.
  • LATAM Pharma
  • Alteogen Inc.
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.

第14章 付録

目次
Product Code: PH6793

Overview

Global Systemic Juvenile Idiopathic Arthritis Market reached US$ 0.87 billion in 2022 and is expected to reach US$ 1.19 billion by 2030.

Juvenile idiopathic arthritis (JIA) is a highly common type of arthritis in kids and teens. Around 10% to 20% of juveniles with JIA carry an infrequent and severe subtype called systemic juvenile idiopathic arthritis (SJIA). "Systemic" indicates that it may impact not just the joints but even additional parts of the body, such as the liver, lungs, and heart. SJIA, often referred to as Still's condition, can transpire at any moment in childhood.

Despite its most typical beginning at approximately two years of age, the males and females are equally impacted. SJIA also varies among different subtypes in that it is exclusively regarded as an autoinflammatory instead of an autoimmune condition. SJIA is additionally extreme and can be more difficult to interpret and treat compared to other types of juvenile idiopathic arthritis. It is a lifelong condition for numerous patients and can persist into adulthood.

The increasing authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global systemic juvenile idiopathic arthritis market growth in the forecast period. Further, the growing cases and research fundings are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Product Approvals and Positive Research Outcomes

The increasing product approvals and positive outcomes from distinct clinical investigations are expected to boost the global market growth in the forecast period. For instnace, in January 2023, the National Medical Products Administration (NMPA) of China authorized the Bio-Thera Solution's biosimilar of Actemra (tocilizumab), BAT1806, a recombinant humanized monoclonal antibody designed to target interleukin-6 receptor (IL-6R). It has been authorized for the treatment of cytokine release syndrome (CRS), rheumatoid arthritis (RA), and systemic juvenile idiopathic arthritis (sJIA). The FDA and EMA have accepted the marketing authorization application for BAT1806/BIIB800.

Moreover, according to a recent study Emapalumab, a completely human anti-interferon-γ (IFNγ), showed effectiveness for causing remission of macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still's disease (AOSD) in individuals who did not obtain effect with usual care with high-dose glucocorticoids, with or without anakinra (Kineret; Sobi) and/or cyclosporin. Emapalumab was investigated in a phase 2, open-label, single-arm trial (NCT03311854) that was executed at 5 locations in France, Italy, Spain, the United Kingdom, and the United States.

Increasing Efforts from Distinct Associations

Increasing Efforts from Distinct Associations to enhance the overall management of Juvenile Idiopathic Arthritis (JIA) and associated conditions. For instance, in March 2023, the Canadian Rheumatology Association (CRA) publicized policies for the screening, monitoring, and treatment of juvenile idiopathic arthritis (JIA)-associated uveitis. Investigations assessing systemic therapies in JIA-associated uveitis are restricted in spite of a uniform therapy procedure and regulatory body clearance for new treatments.

The American College of Rheumatology (ACR)/Arthritis Foundation (AF) policies deliver possibilities for education and lobbying to regional, provincial, and federal regulatory agents and payers to sufficiently access breakthrough treatments. The availability of expert agreement norms for monitoring and controlling JIA-associated uveitis in Canada is expected to assist in normalizing the most elevated standard of care across the nation.

Moreover, at the recent American College of Rheumatology (ACR) Convergence 2021 summit, there was a fascinating discussion targeting adult rheumatologists on how to handle adult patients with juvenile idiopathic arthritis (JIA). Further, the National Institute for Health and Care Excellence, NICE in September 2021, issued a final draft recommendation that guides tofacitinib (also known as Xeljanz and made by Pfizer) as a choice for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in individuals 2 years and older.

High Treatment Cost of Systemic Juvenile Idiopathic Arthritis

The high treatment cost of Systemic Juvenile Idiopathic Arthritis is expected to hamper the global market growth in the forecast period. For instnace, the monetary expense of JIA can be high, in particular, the yearly total for managing juveniles with JIA in the U.S. can vary anywhere from $300 to nearly $45,000, according to a 2021 study in Pediatric Rheumatology. Moreover, the biological medication, Novartis's Ilaris, small vial expenses in-between from $16,000 to $37,000 for each dose relying on insurance coverage.

Further, the entire yearly expenses for the family of an individual with juvenile idiopathic arthritis are considerable, varying from $1,122 to $44,832, with the most elevated dollar payments spent on medication and medical appointments, according to data. These high costs for Systemic Juvenile Idiopathic Arthritis are leaving behind a mjority of impacted individuals hampering the global market growth.

Low Prevalence of the Disorder

The low prevalence of systemic juvenile idiopathic arthritis is expected to hamper the global market growth during the forecast period. For instance, the annual incidence of JIA in New Zealand is 5.1/100,000 and is categorized according to the International League of Associations for Rheumatology (ILAR) standards of which Oligoarticular with 47% of cases and polyarticular with 26% of cases making them the most typical subtypes represented by arthritis in 4 or less and 5 or more joints respectively within the foremost 6 months of interpretation. Less expected subtypes included enthesitis-related arthritis with 15% of cases, systemic JIA accounting for 8% of cases, and psoriatic arthritis with 3% of cases.

While the presence of JIA is quite increased in European children with 7.2 per 100,000 individuals, Maori and Pacific Island children have significantly better potential to provide insufficient predictive features corresponding to European children including cervical involvement, erosive transformations, common area narrowing, and rheumatoid characteristic positive disorder. In Europe, it is estimated that less than one child per 100,000 develops SJIA every year. It is estimated that between 5 and 15 individuals in every 100,000 currently have SJIA, impacting boys and girls equally worldwide.

Segment Analysis

The global systemic juvenile idiopathic arthritis market is segmented based on treatment type, route of administration, age group, end-user and region.

Biologics Treatment Type Expected to Dominate Market

Owing to the increasing market developments in the biologics segment, it is expected to dominate the global market in the forecast period. For instance, in August 2023, CVS Health, introduced Cordavis, a fully held associate that is expected to operate immediately with manufactories to market and/or co-produce biosimilar developments for the U.S. pharmaceutical demand. The Cordavis developments are expected to be FDA-authorized, high-grade, and comfortable for individuals to utilize and are expected to aid in ensuring a constant long-term reserve of inexpensive biosimilars.

As the U.S. pharmaceutical atmosphere continues to grow, biosimilars describe one of the most significant prospects for lowering drug expenses for employers and clients, via Cordavis, CVS Health plans to design a portfolio of developments that it intends to facilitate wider access to biosimilars in the U.S. producing better competition that pushes down expenses while promoting asset in prospective products. The biosimilar market in the U.S. is anticipated to increase from less than $10 billion in 2022 to over $100 billion by 2029.

As its foremost development, Cordavis has acquired Sandoz to market and brought to market Hyrimoz (adalimumab-adaz), a biosimilar for Humira suggested for lowering symptoms and manifestations of moderately to severely active polyarticular JIA in individuals of age 2 years and older. HYRIMOZ can be utilized unaided or in blend with methotrexate in the first quarter of 2024 under a Cordavis private brand. The list expense of Cordavis Hyrimoz will be over 80% lower than the present list cost of Humira.

Geographical Penetration

Increasing Cases of Systemic Juvenile Idiopathic Arthritis

The growing cases of systemic juvenile idiopathic arthritis and distinct government organizations' research funding are expected to boost the North America market, holding the majority of the global market share. For instance, roughly 6,200 (0.10%) Canadians aged 15 years and younger live with diagnosed JIA and about 1,000 (17.1 per 100,000 persons per year) were recently diagnosed in 2016-2017. The preponderance and cases of interpreted JIA typically grow with age and are additionally raised in females (0.13% and 21.1 per 100,000 individuals per year, respectively) corresponding to males (0.08% and 13.4 per 100,000 persons per annum, respectively).

Moreover, in July 2022, the Arthritis Foundation in collaboration with the Childhood Arthritis and Rheumatology Research Alliance (CARRA), supported the recognition of eight CARRA researchers adding to $1,122,755 to perform research desired to enhancing developments in childhood rheumatic disorders, including juvenile idiopathic arthritis, the most typical form of arthritis analyzed in juveniles. The Arthritis Foundation assesses there are almost 300,000 children and teens with arthritis in the United States. Childhood-onset rheumatic disorders enclose different sorts of arthritis and other rheumatic and inflammatory disorders that evolve in children and teens.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Further, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

Since more beds in wards and intensive care units were assigned to COVID-19 patients, considerable surgical divisions registered a reduction in the number of patient visits. The imposition of lockdown as a strategy to flatten the curve of COVID-19 patients also stalled the management of these patients. However, currently majority of healthcare departments have recovered and gained the number of patient vesting's to a standard value.

By Treatment Type

  • Drug Treatment
    • Anti-inflammatories (NSAIDS)
    • Tumor Necrosis Factor (TNF) Blockers
    • Muscle Relaxants
    • Immune Suppressants Drugs
    • Disease Modifying Antirheumatic Drugs
    • Others
  • Biologics
  • Other

By Route of Administration

  • Oral
  • Injectables
  • Other
  • Age Group
    • Infants
    • Childrens
    • Adolescents

By End-User

  • Hospitals
  • Specialty Clinics
  • Academic Research Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2023, CVS Health introduced Cordavis, an entirely owned that is expected to function directly with manufactories to commercialize and/or co-produce biosimilar developments for the U.S. market.
  • In June 2022, Baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, greatly raised the time to condition flare and lowered the frequency of flares in patients with juvenile idiopathic arthritis (JIA), according to the outcomes of a phase 3, placebo-controlled investigation.

Competitive Landscape

The major global players in the market include: Novartis AG, Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Bristol - Myers Squibb Company, Cadila Healthcare Ltd., Genetech, Inc., LATAM Pharma, Alteogen Inc., Johnson & Johnson, and Momenta Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global systemic juvenile idiopathic arthritis market segmentation based on treatment type, route of administration, age group, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of systemic juvenile idiopathic arthritis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global systemic juvenile idiopathic arthritis market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Approvals and Positive Research Outcomes
      • 4.1.1.2. Increasing Efforts from Distinct Associations
    • 4.1.2. Restraints
      • 4.1.2.1. High Treatment Cost of Systemic Juvenile Idiopathic Arthritis
      • 4.1.2.2. Low Prevalence of the Disorder
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Technology Trend
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Drug Treatment*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Anti-inflammatories (NSAIDS)
    • 7.2.4. Tumor Necrosis Factor (TNF) Blockers
    • 7.2.5. Muscle Relaxants
    • 7.2.6. Immune Suppressants Drugs
    • 7.2.7. Disease Modifying Antirheumatic Drugs
    • 7.2.8. Others
  • 7.3. Biologics
  • 7.4. Other

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Injectables
  • 8.4. Other

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. Infants*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Childrens
  • 9.4. Adolescents

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Academic Research Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Hoffmann-La Roche Ltd
  • 13.3. Takeda Pharmaceutical Company Limited
  • 13.4. Bristol - Myers Squibb Company
  • 13.5. Cadila Healthcare Ltd.
  • 13.6. Genetech, Inc.
  • 13.7. LATAM Pharma
  • 13.8. Alteogen Inc.
  • 13.9. Johnson & Johnson
  • 13.10. Momenta Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us